The global prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) is ≈38%, causing serious healthy burdens worldwide.[1, 2] Currently, for the treatment of MASLD, endocrine hormones, including thyroid hormone, glucagon like peptide‐1 (GLP‐1), and fibroblast growth factor‐21 (FGF21), have attracted significant attentions. Here, FGF21 is linked to metabolic dysfunction-associated steatotic liver disease.